Pamela Kunz, MD, FASCO (@pamelakunzmd) 's Twitter Profile
Pamela Kunz, MD, FASCO

@pamelakunzmd

Div Chief GI Onc @YaleCancer | #NETs
Editor-in-Chief, JCO OA @JCO_ASCO | ASCO FCOI: bit.ly/3IPTmtk
Public Voices Fellow of @TheOpEdProject

ID: 2980465697

linkhttps://medicine.yale.edu/profile/pamela_kunz/ calendar_today15-01-2015 22:08:34

4,4K Tweet

8,8K Followers

4,4K Following

Ana I. Velázquez Mañana, MD, MSc, FASCO (@anavmanana) 's Twitter Profile Photo

Our communities exist, they are not going anywhere. Their/our lived experiences are real—no matter what words are banned, no one can erase them. The work will continue, with or without federal funding and support. #WorldCancerDay

Rami Manochakian MD, FASCO Cancer Education (@rmanochakian) 's Twitter Profile Photo

🔥🚨HOT OFF THE PRESS Just published Journal of Clinical Oncology IMPORTANT SPECIAL ARTICLE & #Recommendations for #Academic #MedicalCenters by ASCO on: Promoting Reasonable #CareerExpectations & Maximizing Professional Fulfillment for #Academic #Oncologists PLZ SHARE👇🏻 ascopubs.org/doi/10.1200/JC…

🔥🚨HOT OFF THE PRESS
Just published <a href="/JCO_ASCO/">Journal of Clinical Oncology</a>

IMPORTANT SPECIAL ARTICLE 
&amp; #Recommendations for #Academic #MedicalCenters by <a href="/ASCO/">ASCO</a> on:

Promoting Reasonable #CareerExpectations &amp; Maximizing
Professional Fulfillment for #Academic #Oncologists

PLZ SHARE👇🏻
ascopubs.org/doi/10.1200/JC…
Dr. Cathy Eng (@cathyengmd) 's Twitter Profile Photo

TY TIME for focusing on our concerns for #earlyonset #cancer and providing ⬆️ #cancerawareness and ⬆️education. We may not have an immediate answer but the GOAL is unchanged: Identify reasons for the ↗️ incidence and ⬆️ overall prognosis. #colorectalcancer @VUMC_Cancer

AACR (@aacr) 's Twitter Profile Photo

The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. We urge Congress to restore stability to NIH: brnw.ch/21wQMO3

The AACR is deeply concerned that the Administration’s recent actions are threatening NIH and its mission to accelerate progress for patients with cancer and other diseases that afflict millions of Americans. We urge Congress to restore stability to NIH: brnw.ch/21wQMO3
Yale Cancer Center (@yalecancer) 's Twitter Profile Photo

Congratulations to the Center for Gastrointestinal Cancers team and Michael Cecchini for enrolling the 1st patient in the US in the OrigAMI-2 trial for unresectable or metastatic left-sided colorectal cancer. Learn more about the study: medicine.yale.edu/ycci/clinicalt… #CRC #CRCSM Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp

Congratulations to the <a href="/YaleGICancers/">Center for Gastrointestinal Cancers</a> team and <a href="/Cecchini_OncMD/">Michael Cecchini</a> for enrolling the 1st patient in the US in the OrigAMI-2 trial for unresectable or metastatic left-sided colorectal cancer. Learn more about the study:
medicine.yale.edu/ycci/clinicalt… #CRC #CRCSM
<a href="/SmilowCancer/">Smilow Cancer Hospital</a> <a href="/YaleMed/">Yale School of Medicine</a> <a href="/YNHH/">Yale New Haven Hosp</a>
Jennifer Guerriero, PhD (@jennguerriero) 's Twitter Profile Photo

It was such an honor to be the Keynote speaker along with Pamela Kunz, MD, FASCO in the UPMC Hillman Cancer Center Women’s Initiatives Taskforce Symposium. An incredible day of science and inspiration. Organizers 💪🏼 Overacre Lab Dr Kathryn Schmitz, Michelle Williams, Tullia Bruno, PhD Olja Finn, Annie Im.

It was such an honor to be the Keynote speaker along with <a href="/PamelaKunzMD/">Pamela Kunz, MD, FASCO</a> in the <a href="/UPMCHillmanCC/">UPMC Hillman Cancer Center</a> Women’s Initiatives Taskforce Symposium. An incredible day of science and inspiration. 
Organizers 💪🏼 <a href="/OveracreLab/">Overacre Lab</a> <a href="/fitaftercancer/">Dr Kathryn Schmitz</a>, Michelle Williams, 
<a href="/BcellBruno/">Tullia Bruno, PhD</a> Olja Finn, Annie Im.
NANETS (@nanets1) 's Twitter Profile Photo

Calling all trainees! Get exclusive access to resources, networking, and research opportunities for just $55/year with NANETS! Elevate your career in neuroendocrine tumors. Join today! #NeuroendocrineTumors #NANETS #MedicalCareer

Calling all trainees! Get exclusive access to resources, networking, and research opportunities for just $55/year with NANETS! Elevate your career in neuroendocrine tumors. Join today! 

#NeuroendocrineTumors #NANETS #MedicalCareer
Yale Cancer Center (@yalecancer) 's Twitter Profile Photo

Thank you to Dr. Douglas Evans Medical College of Wisconsin for presenting #GrandRounds + #Schnog Lecture discussing important advances in pretreatment staging, therapy, and palliative care for #pancreaticcancer. Watch his talk now youtube.com/watch?v=7oXlcS…. Smilow Cancer Hospital Yale School of Medicine Yale New Haven Hosp

Thank you to Dr. Douglas Evans <a href="/MedicalCollege/">Medical College of Wisconsin</a> for presenting #GrandRounds + #Schnog Lecture discussing important advances in pretreatment staging, therapy, and palliative care for #pancreaticcancer. Watch his talk now youtube.com/watch?v=7oXlcS…. <a href="/SmilowCancer/">Smilow Cancer Hospital</a> <a href="/YaleMed/">Yale School of Medicine</a> <a href="/YNHH/">Yale New Haven Hosp</a>
Udhayvir Grewal (@ugrewalmd) 's Twitter Profile Photo

COMPETE trial results are out! Presented by Jaume Capdevila Lu177-edo vs Everolimus in G1/2 GEPNETs either 1st line or after progression on SSA (mostly second line). PFS favors PRRT (HR=0.67), interim OS numerically favors PRRT, safety favors PRRT. First phase 3 trial

COMPETE trial results are out! Presented by <a href="/Ja_Capdevila/">Jaume Capdevila</a> 

Lu177-edo vs Everolimus in G1/2 GEPNETs either 1st line or after progression on SSA (mostly second line). 
PFS favors PRRT (HR=0.67), interim OS numerically favors PRRT, safety favors PRRT. 

First phase 3 trial
Sharlene Gill, MD, MPH, MBA, FASCO (@gillsharlene) 's Twitter Profile Photo

#ASCO25 ASCO 4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍 👇my top picks for key abstracts to watch for🌟 ➡️Two GI plenary sessions🏅 MATTERHORN #STCsm Yelena Y. Janjigian MD ATOMIC #dMMR #CRCsm Frank Sinicrope, MD ➡️Clinical Science Symposium

#ASCO25 <a href="/ASCO/">ASCO</a> 
4 weeks away and looks like it is going to be a practice-changing #ASCO25 for #GIcancers👍
👇my top picks for key abstracts to watch for🌟
➡️Two GI plenary sessions🏅
MATTERHORN #STCsm <a href="/YJanjigianMD/">Yelena Y. Janjigian MD</a> 
ATOMIC #dMMR #CRCsm <a href="/FASinicropeMD/">Frank Sinicrope, MD</a> 
➡️Clinical Science Symposium